The local medical landscape is abuzz with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing significant results in early trials for treating obesity. This https://bookmarkcork.com/story22574328/retatrutide-australia-a-potential-solution-for-weight-loss